Literature DB >> 3992209

Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections.

I Nilsson-Ehle, C E Nord, B Ursing.   

Abstract

12 patients with acute bacterial infections were treated with ceftriaxone, 1.5 g intravenously twice daily for 7-13 days. Pharmacokinetic variables were studied in 11 patients. In older subjects, serum half-lives were longer and serum clearances lower than in younger individuals. After the last dose, a larger increase in AUC compared to the first dose was observed in older patients and a biphasic elimination curve appeared in all patients but 2, with a terminal half-life of 15.6 h and 11.4 in old and young subjects, respectively. Estimated biliary clearances showed large individual variation, with a range of 0-16 ml/min X 1.73 m2. Changes in the colonic microflora were pronounced. Almost total disappearance of staphylococci, streptococci and enterobacteria was found, and there was a marked tendency to overgrowth of yeasts and enterococci. One patient with the highest estimated biliary clearance of ceftriaxone developed diarrhoea after 7 days of therapy. A toxin-producing Clostridium difficile was isolated from the stool.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3992209     DOI: 10.3109/00365548509070424

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

1.  The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract.

Authors:  G W Welling; G J Meijer-Severs; G Helmus; E van Santen; R H Tonk; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  MiniBioReactor Array (MBRA) in vitro gut model: a reliable system to study microbiota-dependent response to antibiotic treatment.

Authors:  C A Hobson; L Vigue; S Naimi; B Chassaing; M Magnan; S Bonacorsi; B Gachet; I El Meouche; A Birgy; O Tenaillon
Journal:  JAC Antimicrob Resist       Date:  2022-07-05

5.  Impact of cefotaxime and ceftriaxone on the bowel and vaginal flora after single-dose prophylaxis in vaginal hysterectomy.

Authors:  H H Bräutigam; H Knothe; R Rangoonwala
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 7.  Impact of antimicrobial therapy on the gut microbiome.

Authors:  Amira A Bhalodi; Tjitske S R van Engelen; Harjeet S Virk; W Joost Wiersinga
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

8.  Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients.

Authors:  Hasinika K A H Gamage; Carola Venturini; Sasha G Tetu; Masrura Kabir; Vineet Nayyar; Andrew N Ginn; Belinda Roychoudhry; Lee Thomas; Mitchell Brown; Andrew Holmes; Sally R Partridge; Ian Seppelt; Ian T Paulsen; Jonathan R Iredell
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

9.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.